As pharmaceutical manufacturers push toward lower detection limits, tighter impurity thresholds, and faster development cycles, elemental analysis has become a more critical part of quality and compliance.

Regulatory frameworks such as U.S. Pharmacopeia (USP) <232>, USP <233>, and International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Q3D have formalized and intensified industry focus on elemental impurity testing, particularly for trace-level metals that might present patient safety risks even at very low concentrations.

USP <232> establishes limits for elemental impurities in pharmaceutical products, while USP <233> describes analytical procedures used to evaluate them. ICH Q3D adds a risk-based framework for controlling elemental impurities throughout the product life cycle. Together, these standards have pushed pharmaceutical laboratories toward increasingly sensitive analytical workflows, particularly ICP-MS and ICP-OES systems capable of trace-level detection.

 …